• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    SC 13D/A 1 tm247761d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

     

    Lantern Pharma Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    51654W101

    (CUSIP Number)

     

    Bios Equity Partners, LP

    1751 River Run, Suite 400

    Fort Worth, Texas

    Tel: (817) 984-9197

     

    With a Copy to:

    Rick Jordan

    Polsinelli PC

    2950 Harwood St., Suite 2100

    Dallas, Texas 75201

    Tel: (214) 397-0030

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    February 28, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 51654W101

     

    1  

    NAME OF REPORTING PERSONS

     

    BIOS FUND I, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    371,950 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    371,950 (1)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    371,950 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.5% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 371,950 shares of common stock of the Issuer, par value $0.0001 per share (“Shares”) directly held by Bios Fund I, LP (“Bios Fund I”) as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP, LP (“Bios Fund I QP”) on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, LP (“Bios Fund II”), Bios Fund II QP, LP (“Bios Fund II QP”) and Bios Fund II NT, LP (“Bios Fund II NT”) on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

    1  

    NAME OF REPORTING PERSONS

     

    BIOS FUND I QP, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC 

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    217,553 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    217,553 (1)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    217,553 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.0% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 217,553 Shares directly held by Bios Fund I QP as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

    1  

    NAME OF REPORTING PERSONS

     

    BIOS FUND II, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    137,832 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    137,832 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    137,832 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.3% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 137,832 Shares directly held by Bios Fund II as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BIOS FUND II QP, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    450,118 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    450,118 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    450,118 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.2% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 450,118 Shares directly held by Bios Fund II QP as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BIOS FUND II NT, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    60,256 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    60,256 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    60,256 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.6% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 60,256 Shares directly held by Bios Fund II NT as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BP DIRECTORS, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    26,093 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    26,093 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,093 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.2% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of 26,093 Shares directly held by BP Directors, LP (“Bios Directors”) as of the date hereof.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BIOS EQUITY PARTNERS, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x 

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    615,596 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    615,596 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    615,596 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     5.7% (2) 

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by Bios Directors, in each case, as of the date hereof. Bios Equity Partners, LP (“Bios Equity I”) is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BIOS EQUITY PARTNERS II, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH 

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    648,206 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    648,206 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    648,206 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.0% (2) 

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of (i) 137,832 Shares directly held by Bios Fund II, (ii) 450,118 Shares directly held by Bios Fund II QP and (iii) 60,256 Shares directly held by Bios Fund II NT, in each case, as of the date hereof. Bios Equity Partners II, LP (“Bios Equity II”) is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly held by these entities.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    CAVU MANAGEMENT, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (“Cavu Management”) is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
    (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    BIOS CAPITAL MANAGEMENT, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    PN

      

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP (“Bios Management”) is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
     (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    CAVU ADVISORS, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC (“Cavu Advisors”) is the general partner of Cavu Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
     (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

    1  

    NAME OF REPORTING PERSONS

     

    BIOS ADVISORS GP, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    TEXAS, UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (“Bios Advisors”) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
     (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

                 
    1  

    NAME OF REPORTING PERSONS

     

    LESLIE WAYNE KREIS, JR.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF, OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    UNITED STATES

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
     (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    CUSIP No. 51654W101

     

    1  

    NAME OF REPORTING PERSONS

     

    AARON GLENN LOUIS FLETCHER

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    UNITED STATES

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    -0-

      8  

    SHARED VOTING POWER

     

    1,263,802 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    -0-

      10  

    SHARED DISPOSITIVE POWER

     

    1,263,802 (1)

                 
    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,263,802 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    11.8% (2)

    14  

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Aaron Glenn Louis Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Mr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
     (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

     

     

    Item 1. SECURITY AND ISSUER

     

    This Amendment No. 3 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on June 15, 2020 (the “Original Schedule 13D”), as amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on March 22, 2022 (“Amendment No. 1”), as further amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on December 1, 2023 (“Amendment No. 2” and, together with the Original Schedule 13D and Amendment No. 1, the “Prior Statements”). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the “Shares”), of Lantern Pharma, Inc., a Delaware corporation (the “Issuer”).

     

    The Purpose of this Amendment No. 3 is to disclose the sale of Shares by each of Bios Fund II, LP (“Bios Fund II”), Bios Fund II QP, LP (“Bios Fund II QP”) and Bios Fund II NT, LP (“Bios Fund II NT”) on the open market. Except as otherwise provided herein, each Item of the Prior Statements remains unchanged. Capitalized terms used herein but not defined in this Amendment No. 3 shall have the meaning ascribed to such term in the Prior Statements.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

     

    (a) See rows (11) and (13) of the cover pages to this Amendment No. 3 for the aggregate number of Shares and percentages of the Shares beneficially owned by each of the Reporting Persons. See footnotes (1) and (2), as applicable, of the cover pages to this Amendment No. 3 for the calculations used in determining the percentages of Shares beneficially owned by each of the Reporting Persons.
       
    (b) See rows (7) through (10) of the cover pages to this Amendment No. 3 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) On January 17, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II exercised warrants to purchase 7,347, 54,873 and 16,801, respectively, shares of common stock of the Issuer. Each of Bios Fund II NT, Bios Fund II QP and Bios Fund II paid the exercise price on a cashless basis, resulting in the Issuer withholding 5,475, 40,893 and 12,521, respectively, of the warrant shares to pay the exercise price and issuing Bios Fund II NT, Bios Fund II QP and Bios Fund II the remaining 1,872, 13,980 and 4,280 shares respectively.

    On February 27, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 4,649, 34,371 and 10,620, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.40. These shares were sold in multiple transactions ranging from $4.35 to $4.50. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    On February 28, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 6,909, 51,608 and 15,780, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.85. These shares were sold in multiple transactions ranging from $4.60 to $5.21. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    On February 29, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 1,832, 13,686 and 4,185, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.87. These shares were sold in multiple transactions ranging from $4.62 to $5.33. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
       
    (d) Except as described in this Amendment No. 3 to the knowledge of the Reporting Persons, only the reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.
       
    (e) Not applicable.
       

     

    Item 7. EXHIBITS
       
    A Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: March 1, 2024

     

      BIOS FUND I, LP
         
      By: Bios Equity Partners, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
             
            By: /s/ Daniel Schwarz
              Daniel Schwarz
              Attorney-in-Fact

     

      BIOS FUND I QP, LP
         
      By: Bios Equity Partners, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact

     

     

     

    BP DIRECTORS, LP

       
      By: Bios Equity Partners, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact

     

      BIOS FUND II, LP
         
      By: Bios Equity Partners II, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact

     

      BIOS FUND II QP, LP
         
      By: Bios Equity Partners II, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact

     

     

      BIOS FUND II NT, LP
         
      By: Bios Equity Partners II, LP,
        its general partner
           
        By: Cavu Management, LP,
          its general partner
             
          By: Cavu Advisors, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
           
        By: Bios Capital Management, LP,
          its general partner
             
          By: Bios Advisors GP, LLC,
            its general partner
               
            By:

    /s/ Daniel Schwarz

              Daniel Schwarz
              Attorney-in-Fact
               

      BIOS EQUITY PARTNERS, LP
         
      By: Cavu Management, LP,
        its general partner
           
        By: Cavu Advisors, LLC,
          its general partner
             
          By:

    /s/ Daniel Schwarz

            Daniel Schwarz
            Attorney-in-Fact
         
      By: Bios Capital Management, LP,
        its general partner
           
        By: Bios Advisors GP, LLC,
          its general partner
             
          By:

    /s/ Daniel Schwarz

            Daniel Schwarz
            Attorney-in-Fact

     

      BIOS EQUITY PARTNERS II, LP
         
      By: Cavu Management, LP,
        its general partner
           
        By: Cavu Advisors, LLC,
          its general partner
             
          By:

    /s/ Daniel Schwarz

            Daniel Schwarz
            Attorney-in-Fact
         
      By: Bios Capital Management, LP,
        its general partner
           
        By: Bios Advisors GP, LLC,
          its general partner
             
          By:

    /s/ Daniel Schwarz

            Daniel Schwarz
            Attorney-in-Fact

     

      CAVU MANAGEMENT, LP
         
      By: Cavu Advisors, LLC,
        its general partner
           
        By:

    /s/ Daniel Schwarz

          Daniel Schwarz
          Attorney-in-Fact
           

           
      BIOS CAPITAL MANAGEMENT, LP
         
      By: Bios Advisors GP, LLC
        its general partner
           
        By:

    /s/ Daniel Schwarz

          Daniel Schwarz
          Attorney-in-Fact
       
      CAVU ADVISORS, LLC
         
      By:

    /s/ Daniel Schwarz

        Daniel Schwarz
        Attorney-in-Fact
       
      BIOS ADVISORS GP, LLC
         
      By:

    /s/ Daniel Schwarz

        Daniel Schwarz
        Attorney-in-Fact

     

     

    /s/ Daniel Schwarz

      DANIEL SCHWARZ, as Attorney-in-Fact for Leslie Wayne Kreis, Jr.
       
     

    /s/ Daniel Schwarz

      DANIEL SCHWARZ, as Attorney-in-Fact for Aaron Glenn Louis Fletcher

     

     

    Get the next $LTRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

      DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

      9/2/21 8:59:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

      Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

      5/8/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

      The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern's AI platform, RADR® The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib. This achievement follows the FDA's Orphan Drug Designation for LP-184 in TNBC in 2023 and FDA Fast Track Designation for LP-184 in TNBC in 2024. The average survival for newly diagnosed, metastatic TNBC is estimated at 18 months and presents an annual market opportunity in excess of $4 billion USD.  Lantern Pharma Inc. (NASDAQ:LTRN), an artifi

      5/5/25 8:55:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

      3/11/22 6:29:59 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

      11/2/21 6:34:51 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

      10/7/21 8:16:17 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Lantern Pharma Inc.

      10-K/A - Lantern Pharma Inc. (0001763950) (Filer)

      4/29/25 8:56:12 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Lantern Pharma Inc.

      10-K - Lantern Pharma Inc. (0001763950) (Filer)

      3/27/25 4:05:45 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Lantern Pharma Inc. (0001763950) (Filer)

      3/27/25 4:03:28 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Financials

    Live finance-specific insights

    See more
    • Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

      Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

      5/8/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

      Webcast to be held Thursday, March 27th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2024 operating and financial results webcast on Thursday, March 27, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2024 and provide guida

      3/20/25 8:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Keyser D Jeffrey exercised 3,832 in-the-money shares at a strike of $3.13 (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      7/26/24 4:15:16 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Keyser D Jeffrey

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      7/17/24 4:30:16 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Maccecchini Maria-Luisa

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      7/17/24 4:30:17 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      3/1/24 4:10:40 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

      SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

      2/14/24 4:05:49 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      12/1/23 6:02:25 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care